SCHEMBL30749030

SCHEMBL30749030

Clc1ncc2c(n1)N(c1ccc(Oc3ccccc3)cc1)CC21CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 4/20 0.40
PDE4B Q07343 1/20 0.37
MAPT P10636 1/20 0.36
PLCG1 P19174 1/20 0.34
CTSG P08311 1/20 0.34
CMA1 P23946 1/20 0.34
LTA4H P09960 1/20 0.33
MGLL Q99685 2/20 0.32
MMP2 P08253 2/20 0.32
MMP3 P08254 2/20 0.32
MMP9 P14780 2/20 0.32
MMP13 P45452 2/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
CASP3 P42574 1/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748843 0.91 PDE4B (0.43) PIN1PDE4BMAPTCTSGCMA1
SCHEMBL30749020 0.86 PIN1 (0.40) PIN1MAPTPLCG1CTSGCMA1
SCHEMBL30749095 0.84 PIN1 (0.36) PIN1PDE4BMAPT
SCHEMBL31691440 0.78 PTPN11 (0.34) PDE4B
SCHEMBL30748910 0.76 PDE4B (0.34) PDE4B
SCHEMBL30748809 0.74 CCNE1 (0.45) PIN1MAPTPLCG1MGLLMMP2
SCHEMBL30749104 0.74 PDE4B (0.43) PDE4BMGLL
SCHEMBL30749019 0.73 PDE4B (0.40) PDE4BMAPT
SCHEMBL30749107 0.71 PSEN1 (0.45) PIN1MAPTPLCG1LTA4H
SCHEMBL30749013 0.70 ALDH1A1 (0.44) MAPTMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT PIN1 944/4885PDE4B 2287/4885MAPT 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.